Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

NCT07010835 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: YK012

Sponsor

Excyte Biopharma Ltd